Biomanufacturing Media

  1. Achieving mRNA-LNP Delivery Beyond The Liver 11/28/2022

    In this segment, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, discuss which ongoing industry efforts to improve LNPs and the RNA/mRNA cargo they're watching closely that could help the RNA industry move beyond hepatic delivery.

  2. Q&A On LNP Cell-Specific Delivery 11/28/2022

    In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery for Strand Therapeutics, outline several examples of foundational research that could provide insights into how we attain more specific cellular uptake of LNPs.

  3. Defining A "Next-Gen" LNP 11/28/2022

    Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, share their expectations on which scientific advancements/characteristics will be most important for LNP-delivery of mRNA/RNA cargo in the future.

  4. Q&A On Formulation & Stability Of LNPs 11/28/2022

    Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, address audience questions around the importance of drug substance and drug product stability in efficient delivery in this segment of the Bioprocess Online Live! event LNPs & Beyond: Opportunities in RNA Delivery.

  5. mRNA's Future Beyond The COVID Vaccines 11/28/2022

    In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, unpack which learnings can be adapted from ASO-LNPs to mRNA/LNPs and from mRNA vaccines to mRNA therapeutics. They also touch upon which learnings cannot be neatly carried over from these previous success stories.

  6. The Scientific Underpinnings Of mRNA/LNPs 11/28/2022

    In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, share their thoughts on the scientific-research and CMC-related reasons that have made the lipid nanoparticle the “darling” of the delivery world for mRNA/RNA products today.

  7. Accelerate Stability Studies To Optimize An Antigen For HIV-Vaccine Research 11/21/2022

    Walk through the process of selecting an optimal buffer for a vaccine antigen and some steps you can follow to help make your own decision.

  8. CHT Prepacked Process-Scale Columns 11/21/2022

    Learn more about one company's prepacked column offerings and the standardized design and format available in a range of diameters and bed volumes.

  9. Biopharma Resilience: CDMOs Secure Supply Chain Management 10/21/2022

    Learn how SanKav Pharmaceuticals provides available medicine to market through available components, resources and raw materials that support on-time production lines and biomanufacturing processes.

  10. RNA-LNP Manufacturing Technology Delivering Transformative Medicines 10/13/2022

    NxGen™ microfluidic technology enables controlled and precise assembly of high-quality, uniform LNPs, ensuring reproducible scale-up of RNA-LNPs while maximizing drug loading and particle quality.